Clinical Trials
19 trialsNCT04106531 2025-12-05
Prolac-10
Ohio State University
Terminated
NCT03515603 2023-05-17
Endocrine Outcome of Surgery for Pituitary Adenoma
University of Ulm
Phase NA Terminated
NCT05338125 2023-03-13
Electrophysiology of the Human Pituitary Gland
Leiden University Medical Center
Phase NA Terminated
NCT03930771 2022-08-09
TMZ-Cap
Weill Medical College of Cornell University
Phase 2 Terminated
NCT02419664 2022-03-31
Ga-68-DOTATOC -PET in the Management of Pituitary Tumours
Göteborg University
Phase 3 Terminated
NCT01861717 2021-09-30
A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.
Saint John's Cancer Institute
Phase 4 Terminated
NCT02749227 2021-04-27
PASSILCORT
Columbia University
Phase 2 Terminated
NCT02743442 2021-03-29
ROBOPHYSE
Fondation Ophtalmologique Adolphe de Rothschild
Phase NA Terminated
NCT01915303 2020-09-18
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
Novartis
Phase 2 Terminated
NCT00616642 2020-08-14
Rosiglitazone in Treating Patients With Pituitary Tumors
Jonsson Comprehensive Cancer Center
Phase 2 Terminated
NCT00005664 2019-12-16
Evaluation of Patients With Endocrine-Related Conditions
National Institutes of Health Clinical Center (CC)
Terminated
NCT01966809 2019-08-20
Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas
Medical College of Wisconsin
Phase 2 Terminated
NCT02629549 2019-08-06
Intraoperative Imaging of Pituitary Adenomas by OTL
University of Pennsylvania
Phase 1 Terminated
NCT00929669 2017-11-28
LAR
University of Pennsylvania
Phase 2 Terminated
NCT00958841 2016-07-26
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
Novartis
Phase 2 Terminated
NCT00798057 2015-10-05
PI01
University of Florida
Terminated
NCT02105337 2015-03-11
Tegaderm and Visual Evoked Potentials
Rutgers, The State University of New Jersey
Terminated
NCT01088763 2014-11-05
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00646308 2011-04-26
Assessment of Cardiovascular Risk Markers in Growth Hormone Deficient Patients With Nonsecreting Pituitary Adenomas
Columbia University
Terminated